Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Systemic diseases and infections: current questions]

O Lortholary1, T Généreau, B Jarrousse

  • 1Service de Médecine interne, Université Paris-Nord, Bobigny.

Presse Medicale (Paris, France : 1983)
|March 2, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Digestive manifestations of systemic vascular diseases].

La Revue de medecine interne·2006
Same author

Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis.

Kidney international·2006
Same author

[Eosinophil granule cationic proteins: eosinophil activation markers].

La Revue de medecine interne·2006
Same author

[Infections and lymphoma during prolonged immunosuppression in vascular diseases].

La Revue de medecine interne·2006
Same author

Skin manifestations in vasculitis and erythema nodosum.

Clinical and experimental rheumatology·2006
Same author

Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.

Annals of the rheumatic diseases·2006

Patients with connective tissue diseases face high infection risks due to their conditions and treatments. Prophylaxis for Pneumocystis pneumonia is crucial, especially for Wegener's granulomatosis patients, and immunosuppression should be delayed until infections clear.

Area of Science:

  • Rheumatology
  • Infectious Diseases
  • Immunology

Background:

  • Connective tissue diseases (CTDs) significantly increase patient morbidity and mortality due to infections.
  • Both the underlying systemic disorders and immunosuppressive therapies contribute to heightened infectious risks.
  • Specific CTDs like Systemic Lupus Erythematosus and Wegener's Granulomatosis are linked to a greater susceptibility to infections.

Purpose of the Study:

  • To highlight the significant infection risks in patients with connective tissue diseases.
  • To emphasize the importance of prophylactic measures against infections, particularly Pneumocystis carinii pneumonia.
  • To provide guidance on managing immunosuppressive therapy in the context of active infections.

Main Methods:

  • Review of existing literature on infections in CTD patients.

Related Experiment Videos

  • Analysis of risk factors associated with specific CTDs and immunosuppressive treatments.
  • Evaluation of current prophylactic strategies and treatment guidelines.

    • Main Results:

    • Patients with CTDs experience substantial morbidity and mortality from infections.
    • Wegener's granulomatosis and Systemic Lupus Erythematosus confer a higher risk of infection.
    • Primary prophylaxis for Pneumocystis carinii pneumonia is recommended for Wegener's granulomatosis patients and other CTD patients with CD4 counts below 200/mm³.

    Conclusions:

    • Systematic primary prophylaxis for Pneumocystis carinii pneumonia is essential in high-risk CTD patients.
    • Intensifying immunosuppression should be deferred until all infections are resolved.
    • Careful management of infections is critical for improving outcomes in CTD patients.